The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020.The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020.
The drug was associated with a relative reduction in clinical decline of 8% in Graduate 1 and 6% in Graduate 2 compared with the placebo, but those results were not statistically reliable, the company said in a statement. The quest to develop an Alzheimer’s drug, targeting beta-amyloid or other molecules, has been beset by a long list of study failures.
Most of the 55 million people suffering from dementia worldwide are believed to be affected by Alzheimer’s disease,according to the World Health Organization. In 2030, dementia is expected to affect 78 million.Berenberg analysts have put a 50% probability on Roche achieving 10 billion Swiss francs in peak annual gantenerumab sales. Other analysts have not included the drug candidate in their group revenue estimates, due to uncertainty.
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: SABCNews - 🏆 37. / 51 Прочитайте больше »